reversible Lp-PLA2 inhibitors (GlaxoSmithKline)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug Namereversible Lp-PLA2 inhibitors (GlaxoSmithKline)

Drug Alias Namereversible lipoprotein-associated phospholipase A2 inhibitors (GlaxoSmithKline)reversible Lp-PLA2 inhibitors (SmithKline Beecham)Substituted Pyrimidin-4-Ones (GlaxoSmithKline)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPhospholipases A2 inhibitors

TargetsPhospholipases A2

Therapy Area/IndicationsAtherosclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSmithkline Beecham Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc Smithkline Beecham Pharmaceuticals

Active IndicationsN/A

Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A